Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 4Recruiting 3Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 14Carcinoma, Non-Small-Cell Lung 9Colorectal Neoplasms 7Stomach Neoplasms 6Triple Negative Breast Neoplasms 5Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Melanoma 3Urinary Bladder Neoplasms 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Extranodal NK-T-Cell 2Liver Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Advanced Biliary Tract Cancer 2Urothelial Carcinoma Bladder 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Radiation Pneumonitis 1

Interventions

Gemcitabine 13Oxaliplatin 9Capecitabine 6lenvatinib 5apatinib 5Cisplatin 5tislelizumab 4Surgical Procedures, Operative 4Radiofrequency Ablation 4Neoadjuvant Therapy 4Fluorouracil 4toripalimab 3sintilimab 3Radiotherapy 3Leucovorin 3Irinotecan 3regorafenib 2pembrolizumab 2durvalumab 2camrelizumab 2Stents 2Photochemotherapy 2Immunotherapy 2Hepatectomy 2Folfox protocol 2Everolimus 2Drug Therapy 2Cholangiopancreatography, Endoscopic Retrograde 2Blood Specimen Collection 21-phenyl-3,3-dimethyltriazene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Cholangiocarcinoma × tislelizumab × Clear all
NCT06134193 2023-11-18

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
41 enrolled
Gastrointestinal

Carcinoma, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05400902 2023-04-13

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University

Phase 2 Unknown
17 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT04782804 2022-08-18

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Fudan University

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05290116 2022-08-05

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University

Phase 2 Unknown
17 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡